Isomorphic Labs at 5: AI drug design shows evidence across disease classes
jeffclune · x · 2026-09-30
Isomorphic Labs co-founder Max Jaderberg reflects on five years since the company's 2021 founding, which grew from conviction that deep reinforcement learning principles could be applied to engineering new medicines. The company now says it has compelling evidence its AI can unlock therapeutics across a wide range of disease classes, and argues the technology will fundamentally change drug discovery and development. Jeff Clune amplified the piece, noting frontier-science breakthroughs come from years of method development and engineering, not luck.
More from AGI Musings
- Software Is Dead, Long Live Data-for-Synthesis: Reddit Debates the Agent Era — Happy_Conference8401 · 2026-09-30
- The Underappreciated AGI Joke: A Baby That Could Talk Would Be Worth Many Hogs — S_OhEigeartaigh · 2026-09-30
- 36% of US public companies report a materially harmful AI incident, EY survey of 200+ execs finds — GaryMarcus · 2026-09-30
- The Ordinary World Quietly Became the Future While We Were Living in It — DistractedDendrite · 2026-09-30
- Researcher: More Worried AI Firms Get 'Looted' Than AI Killing Us All — chris_j_paxton · 2026-09-30
- YC's S26 Batch Has More RL Environment Startups Than AI-for-Sales Companies — burny_tech · 2026-09-30